Centre clarifies on 3rd wave possibility after Omicron dete...| MENAFN.COM

Monday, 24 January 2022 07:04 GMT

Centre clarifies on 3rd wave possibility after Omicron detection


(MENAFN- IANS) >

New Delhi, Dec 3 (IANS) Omicron cases are increasingly being reported from countries outside of South Africa. India has also reported two cases of Omicron Covid variant and is likely to spread to more countries.

'Given the fast pace of vaccination in India and high exposure to Delta variant as evidenced by high seropositivity, the severity of the disease is anticipated to be low. However, scientific evidence is still evolving,' said the Health Ministry on Friday. It added further that the scale and magnitude of rise in cases and most importantly the severity of disease that will be caused is still not clear.

On the question of existing vaccine efficacy against this variant, the health ministry has said that there is no evidence to suggest that existing vaccines do not work on Omicron, some of the mutations reported on Spike gene may decrease the efficacy of existing vaccines. However, vaccine protection is also by antibodies as well as by cellular immunity, which is expected to be relatively better preserved.

'Hence vaccines are expected to still offer protection against severe disease, and vaccination with the available vaccines is crucial. If eligible, but not vaccinated, one should get vaccinated,' it added.

The response measures for all variants of concern, including Omicron, is the same as that for SARs CoV2. The ministry has said that the precautions and steps to be taken remain the same as before. 'It is essential to mask yourself properly, take both doses of vaccines (if not yet vaccinated), maintain social distancing and maintain good ventilation to the maximum possible', said the ministry in a statement.

The government is monitoring the situation closely and is issuing suitable guidelines, said the ministry, adding that the scientific and medical community is geared up for developing and deploying diagnostics, carrying out genomic surveillance, generating evidence about viral and epidemiologic characteristics, and development of therapeutics.

--IANS

avr/dpb

MENAFN03122021000231011071ID1103298469


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.